AUTHORS
Julia Miriam Lew, MD, Sarah Alexander, MD2, Gregory Michael Taylor Guilcher, MD, FRCPC, DRCPSC, FAAP3, Pierre-Philippe Piche Renaud, MD4, Nawar Dakhallah, MD5, Kriti Kumar, MD6
AFFILIATIONS
1 Hospital for Sick Children, Toronto, Ontario, Canada
2 BC Children's Hospital, Vancouver, British Columbia, Canada
3 Alberta Children's Hospital, Calgary, Alberta, Canada
4 Hospital for Sick Children, Toronto, Ontario, Canada
5 CHU Sainte-Justine, Montreal, Quebec, Canada
6 Hospital for Sick Children, Toronto, Ontario, Canada
ABSTRACT
Background: Children treated for cancer lose vaccine-derived immunity through chemotherapy-induced depletion of memory B cells and plasma cells. Existing re-vaccination recommendations diverge, with prior work documenting wide variation in post-treatment titre use and re-vaccination practice. Critically, none of these recommendations can be applied to children treated with many newer immunotherapies, for whom vaccination data have not been published — yet these agents are now used in frontline therapy. This study characterized current Canadian re-vaccination and serologic testing practice, establishing the baseline against which immunotherapy-era guidance will need to be developed.
Methods: An electronic REDCap survey was distributed between June and August 2026 to pediatric oncology physicians and nurse practitioners at all 16 Canadian pediatric oncology centres, via the Canadian Childhood Cancer and Blood Disorders Network (C17) listserv and site contacts. Domains included preferred re-vaccination strategy, timing of re-initiation for live-attenuated and non-live vaccines, guideline use, serologic titre measurement, and perceived barriers. Questions pertained to patients who had not undergone hematopoietic stem cell transplantation. Respondents selected from among four approaches: universal re-vaccination (routine boosters), serology-guided re-vaccination (boosters based on titre levels), individualized decision-making without a standardized protocol, or no post-treatment re-vaccination practice. Responses were analyzed descriptively at the question level; denominators reflect respondents answering each item, as completion was not required and select items permitted more than one response. A response rate could not be calculated, as listserv distribution precluded enumeration of clinicians reached.
Results: Fifty-three clinicians from 15 of 16 (94%) Canadian pediatric oncology centres provided responses; item-level denominators ranged from 43 to 53. Of 51 reporting their role, 42 (82%) were physicians and 9 (18%) were nurse practitioners. Most (43/53, 81%) reported caring for children with leukemia or lymphoma.
A serology-guided approach predominated (23/44, 52%), followed by universal re-vaccination (13/44, 30%), no post-treatment re-vaccination practice (5/44, 11%), and individualized decision-making (3/44, 7%). Institutional guidelines informed practice for 28/47 (60%); 45/47 (96%) reported awareness of the COG guidelines.
Preferred timing for re-initiating non-live vaccines was 3 months for 18/44 (41%), 6 months for 25/44 (57%), and 12 months for 1/44 (2%). For live vaccines, timing was 6 months for 22/44 (50%) and ≥12 months for 17/44 (39%); the remainder specified 3 months (n=2), 9 months (n=2), or absolute lymphocyte count rather than a fixed interval (n=1).
Serologic titres were routinely assessed before therapy by 22/44 (50%) and after therapy by 22/44 (50%). Serologic titres were rarely or never checked by 16/44 (36%) before therapy and 15/44 (34%) after therapy. Only 10/44 (23%) routinely verified serologic response after re-vaccination. Among centres contributing more than one respondent, agreement on overall re-vaccination approach was common, whereas timing of re-initiation of vaccines and use of serologic titres frequently differed.
Clinician-perceived patient and family barriers included vaccine hesitancy (25/44, 57%), additional healthcare visits (19/44, 43%), and uncertainty about the need for re-vaccination (16/44, 36%). Provider barriers included uncertainty regarding indications for serologic testing (18/43, 42%), lack of institutional guidelines (16/43, 37%), limited access to vaccine records (16/43, 37%), and lack of knowledge of patients' vaccine needs (16/43, 37%). Most (41/47, 87%) agreed that standardized guidelines are needed.
Conclusions: Canadian pediatric oncology re-vaccination practice varies substantially and is not anchored to a single guideline. A serology-guided approach predominated, yet titres are named as the decision rule more often than they are measured or verified. Within centres, clinicians generally agreed on approach but not on timing, indicating that variation is not solely a between-centre guideline gap. In the era of broad implementation of novel immunotherapies for children with cancer, prospective data are needed to inform optimal re-vaccination strategies in this population.
DISCLOSURES
Julia Miriam Lew, MD: No relevant conflicts of interest to declare.